Zusammenfassung
Anliegen Diese Kasuistik beschreibt einen Fall eines 21-jährigen Patienten mit schwerer, orofazialer,
tardiver Dyskinesie (TD), welcher eine augmentative Behandlung mit Pramipexol (D3-Agonist)
zur vorbestehenden polypharmazeutischen Therapie erhielt. Methode Es handelt sich um einen klinischen Behandlungsversuch. Ergebnisse Es kam zu einer relativen Besserung der orofazial betonten TD mit positivem Einfluss
auf die Affektmodulation. Schlussfolgerung Pramipexol erwies sich als mögliche zusätzliche Behandlungsoption der TD.
Abstract
Objective Tardive dyskinesia (TD) is still a severe side effect induced by old neuroleptic
drugs as well as modern atypical ones. The treatment is inefficient and often experimental.
Aim of this study was to examine the effect of pramipexole, a dopamine D3 receptor
agonist, in a severe case of oro-facial TD. Method The TD of a 21 year old male patient with severe oro-facial occurrence was assessed
by the Simpson et al scale before starting pramipexole therapy. Reevaluation was made
during therapy and when the maximum dose of 1.44 mg a day was reached. Standard therapy
with clozapine, valproic acid, oxazepam, bornaprin hydrochlorid and tiapride was continued
as before. Results Oral dyskinesia decreased 20 % and no side effects were observed. Regarding psychopathology
the patient was more interested in work and showed better concentration in therapies.
Conclusion Pramipexole could be a new promising add-on therapy in severe TD. Additionally, the
low plasma binding and mild side effect profile of pramipexole makes it safe in combination
with antipsychotic therapy.
Schlüsselwörter
Antipsychotika - Pramipexol - tardive Dyskinesie - D3-Agonist
Key words
tardive dyskinesia - D3 agonism - pramipexole
Literatur
- 1
Soares-Weiser K, Fernandez H H.
Tardive Dyskinesia.
Semin Neurol.
2007;
27
159-169
- 2
Tarsy D, Baldessarini R J.
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics.
Mov Disord.
2006;
21
589-598
- 3
de Jesus Mari J, Lima M S, Costa A N, Alexandrino N, Rodrigues-Filho S, de Oliviera I R,
Tollefson G D.
The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial
comparing olanzapine with conventional treatment for schizophrenia and related disorders.
Eur Arch Psychiatry Clin Neurosci.
2004;
254
356-361
- 4
Malik P, Andersen M B, Peacock L.
The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of
tardive dyskinesia.
Pharmacol Biochem Behav.
2004;
78
805-810
- 5
Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz W F, Möller H J.
WFSBP Task Force on Treatment Guidelines for Schizophrenia.
World J Biol Psychiatry.
2006;
7
5-40
- 6
Simpson G M, Lee J H, Zoubok B, Gardos G.
A rating scale for tardive dyskinesia.
Psychopharmacol.
1979;
64
171-179
- 7
Diehl A, Braus D F, Büchel C, Krumm B, Medori R, Gattaz W F.
Tardive dyskinesia: pergolid, a possible therapeutic option.
Psychiat Prax.
2003;
30
333-337
- 8
Lemke M R, Brecht H M, Koester J, Kraus P H, Reichmann H.
Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning
in Parkinson's disease.
J Neurol Sci.
2006;
248
266-270
Dr. Rehor Gerald
LKH Rankweil, Abteilung für Psychiatrie I
Obere Venserstraße 19
6773 Vandans, Österreich
Email: gerald@rehor.at
